Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGALITY: GP2015 vs Enbrel in Psoriasis
NCT01891864Phase 3Completed
- Sponsor
- Sandoz
- Start
- Jun 2013
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of GP2015 in plaque psoriasis (2 arms), sponsored by Sandoz. Primary endpoint: PASI 75 Response Rate at 12 weeks. Started Jun 2013; status: completed.
02
Drugs
GP2015
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01891864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01891864.